Your browser is no longer supported. Please, upgrade your browser.
Settings
THLD Threshold Pharmaceuticals, Inc. daily Stock Chart
THLD [NASD]
Threshold Pharmaceuticals, Inc.
Index- P/E1.12 EPS (ttm)0.54 Insider Own10.38% Shs Outstand73.90M Perf Week-11.15%
Market Cap44.65M Forward P/E- EPS next Y-0.29 Insider Trans0.00% Shs Float66.40M Perf Month20.84%
Income49.30M PEG- EPS next Q-0.08 Inst Own33.40% Short Float1.17% Perf Quarter28.55%
Sales65.90M P/S0.68 EPS this Y266.70% Inst Trans-5.96% Short Ratio0.85 Perf Half Y-29.74%
Book/sh0.32 P/B1.89 EPS next Y19.40% ROA122.80% Target Price- Perf Year162.70%
Cash/sh0.38 P/C1.58 EPS next 5Y- ROE157.20% 52W Range0.21 - 1.48 Perf YTD37.32%
Dividend- P/FCF- EPS past 5Y25.20% ROI66.00% 52W High-59.18% Beta3.17
Dividend %- Quick Ratio7.90 Sales past 5Y- Gross Margin- 52W Low187.71% ATR0.06
Employees17 Current Ratio7.90 Sales Q/Q- Oper. Margin- RSI (14)53.85 Volatility10.01% 9.56%
OptionableYes Debt/Eq0.00 EPS Q/Q11.60% Profit Margin74.80% Rel Volume0.83 Prev Close0.55
ShortableYes LT Debt/Eq0.00 EarningsMar 09 BMO Payout0.00% Avg Volume911.01K Price0.60
Recom2.00 SMA203.11% SMA5015.49% SMA2002.19% Volume756,599 Change9.02%
Dec-07-15Downgrade Piper Jaffray Overweight → Neutral
Sep-05-14Initiated H.C. Wainwright Buy $12
Jul-08-14Resumed Brean Capital Buy $15
Oct-01-12Reiterated Stifel Nicolaus Buy $13 → $15
Sep-20-12Initiated Maxim Group Buy $10
Aug-24-12Initiated Stifel Nicolaus Buy $13
Jul-10-12Initiated William Blair Outperform
Apr-02-12Initiated Mizuho Buy $15
Mar-19-12Reiterated JMP Securities Mkt Outperform $7 → $12
Mar-09-12Reiterated MLV & Co Buy $5 → $15.40
Dec-22-10Initiated MLV Capital Buy $5
Jan-26-17 07:10AM  Research Reports Coverage on Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold Pharma, and AmpliPhi Biosciences PR Newswire
Jan-13-17 02:35PM  Hurry! These 5 Stocks Are About to Break Out Explosively +8.51%
Dec-19-16 08:02AM  Threshold Pharmaceuticals and National Cancer Institute to Collaborate on Drug Candidate TH-3424 GlobeNewswire
Dec-12-16 05:44PM  Is Threshold Pharmaceuticals, Inc. (THLD) A Good Stock To Buy? at Insider Monkey -7.41%
Nov-15-16 04:05PM  Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel Healthcare Conference 2016 GlobeNewswire
01:04PM  THRESHOLD PHARMACEUTICALS INC Financials
06:19AM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
02:09AM  Merck KGaA expects profit gain from lower development costs
Nov-07-16 08:13AM  Threshold Pharmaceuticals posts 3Q loss
08:00AM  Threshold Pharmaceuticals Reports Third Quarter Financial Results GlobeNewswire
06:07AM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
Oct-25-16 08:00AM  Caris Life Sciences and Threshold Pharmaceuticals Collaborate to Utilize Caris' ADAPT Biotargeting System in the Development Program for Evofosfamide PR Newswire
Oct-18-16 06:04AM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Oct-03-16 11:25PM  Is Threshold Pharmaceuticals a Buy? (THLD) at Investopedia -11.76%
Sep-30-16 05:16PM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fi -42.37%
09:56AM  Why Investors Are Buzzing About Threshold Pharmaceuticals, Enbridge, Facebook and More at Insider Monkey
Sep-29-16 06:17PM  COO of Threshold Pharmaceuticals to Resign (THLD) at Investopedia
06:04PM  Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities GlobeNewswire
05:21PM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Direct
Sep-14-16 08:20AM  Key FDA Decisions and Trial Results Coming in the Next 2 Months at 24/7 Wall St.
Sep-13-16 05:03PM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other Events -7.75%
Sep-10-16 10:19AM  Hedge Funds Think These Penny Stocks Are Poised to Explode at Insider Monkey
Sep-06-16 11:18AM  ETFs with exposure to Threshold Pharmaceuticals, Inc. : September 6, 2016
04:02AM  Biotech Movers and Shakers: Threshold Pharmaceuticals, Inc. (THLD) and Dynavax Technologies Corporation (DVAX) at Insider Monkey
Aug-22-16 02:26PM  One Reason Why Threshold Pharma (THLD) Stock Is Jumping Today +17.24%
Aug-01-16 08:19AM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
08:07AM  Threshold Pharmaceuticals posts 2Q loss
08:00AM  Threshold Pharmaceuticals Reports Second Quarter Financial Results GlobeNewswire
Jul-20-16 04:50PM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Jun-27-16 05:12PM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -5.26%
Jun-09-16 09:42AM  Most Popular Healthcare Penny Stocks Among Hedge Funds at Insider Monkey
Jun-06-16 08:30AM  Threshold Pharmaceuticals Highlights Multiple Presentations at the 2016 ASCO Annual Meeting GlobeNewswire +8.70%
06:49AM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Jun-01-16 08:30AM  Threshold Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference GlobeNewswire
May-05-16 06:28PM  Threshold Pharmaceuticals posts 1Q loss
04:46PM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:02PM  Threshold Pharmaceuticals Reports First Quarter Financial Results GlobeNewswire
Apr-29-16 03:32PM  ETFs with exposure to Threshold Pharmaceuticals, Inc. : April 29, 2016
Apr-22-16 05:26PM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-28-16 09:40AM  ETFs with exposure to Threshold Pharmaceuticals, Inc. : March 28, 2016
Mar-21-16 08:18AM  Threshold Pharmaceuticals Appoints Stew Kroll as Chief Operating Officer at noodls
08:00AM  Threshold Pharmaceuticals Appoints Stew Kroll as Chief Operating Officer GlobeNewswire
Mar-18-16 11:30AM  Threshold (THLD): Evofosfamide May Be Effective in Some Pancreatic Cancer Patients
Mar-17-16 04:07PM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
10:00AM  ETFs with exposure to Threshold Pharmaceuticals, Inc. : March 17, 2016
Mar-16-16 10:59AM  Threshold Pharmaceuticals, Inc. :THLD-US: Earnings Analysis: 2015 By the Numbers
Mar-14-16 09:00AM  Biotech Trade Report Accesswire
Mar-11-16 10:56AM  Top Penny Stocks to Watch, Friday 3/11/2016 Accesswire +83.33%
Mar-10-16 07:29PM  Threshold Pharmaceuticals posts 4Q profit -9.09%
04:13PM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  Threshold Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results GlobeNewswire
Mar-01-16 07:00AM  Threshold Pharmaceuticals Announces Presentation and Webcast at the Cowen and Company 36th Annual Health Care Conference GlobeNewswire
Feb-12-16 05:14PM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Jan-22-16 05:12PM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Jan-11-16 07:00AM  Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany Agree to Key Terms for the Licensing Back of All Rights to Evofosfamide to Threshold
06:14AM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Dec-22-15 11:12AM  Threshold Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Dec-18-15 05:25PM  After cancer drug trials crash, Peninsula biotech sheds one-third of jobs at bizjournals.com -5.56%
04:24PM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Direct
04:05PM  Threshold Pharmaceuticals Announces Workforce Reduction Marketwired
Dec-14-15 11:08AM  The Only Bit of "Good News" From 2015 Accesswire -9.80%
Dec-12-15 10:25AM  5 Key BioPharma Movers That Cannot Be Ignored at 24/7 Wall St.
10:20AM  5 Companies That Absolutely Destroyed Shareholders This Past Week at 24/7 Wall St.
Dec-08-15 09:45AM  INVESTOR UPDATE: NASDAQ/NYSE Volatility Alert for December 8, 2015 Accesswire
Dec-07-15 03:50PM  Peninsula biotech sinks on two cancer failures at bizjournals.com -82.04%
01:13PM  Why Are Investors Selling These Stocks Today? at Insider Monkey
12:15PM  Why Threshold Pharma Is Imploding at 24/7 Wall St.
11:04AM  Threshold Pharmaceuticals stock plunges after drug trial disappoints at MarketWatch
08:55AM  GE pulls plug on Electrolux deal; Keurig shares surge on buyout; Chipotle hits 52-week low
07:49AM  Oil puts pressure on stocks; Pres. Obama calls on tech giants; Google Ventures' new strategy
07:22AM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
01:00AM  Threshold Pharmaceuticals Announces Its Two Phase 3 Studies Evaluating Evofosfamide Did Not Meet Primary Endpoints Marketwired
Dec-02-15 11:59AM  Notable option activity in equities
06:11AM  Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics at TheStreet
Nov-30-15 01:49PM  Hedge Funds Are Crazy About Threshold Pharmaceuticals, Inc. (THLD) at Insider Monkey
Nov-24-15 04:07PM  Here is What Hedge Funds Think About Luxfer Holdings PLC (LXFR) at Insider Monkey
Nov-22-15 09:12AM  Beyond Chemotherapy: 4 Unique Ways Drug Developers Are Fighting Back Against Cancer at Motley Fool
Nov-18-15 07:16AM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
07:00AM  Threshold Pharmaceuticals Enters Into Definitive Co-Promotion Agreement for Evofosfamide With Merck KGaA, Darmstadt, Germany Marketwired
Nov-11-15 07:00AM  Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2015 Healthcare Conference Marketwired
Nov-06-15 07:00AM  Preclinical Studies Find That Tarloxotinib May Overcome Resistance to EGFR Tyrosine Kinase Inhibitors Marketwired
Nov-05-15 02:37PM  Threshold Pharmaceuticals, Inc. Value Analysis (NASDAQ:THLD) : November 5, 2015
10:19AM  Threshold Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : November 5, 2015
Nov-03-15 08:10AM  Threshold Pharmaceuticals Announces Preclinical Data on Combination of Evofosfamide With Immune Checkpoint Inhibitors to Be Presented at the SITC 2015 Meeting Marketwired
Nov-02-15 11:30AM  THLD Exited Third Quarter with a Strong Balance Sheet +5.77%
07:16AM  THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:13AM  Threshold Pharmaceuticals posts 3Q loss
07:00AM  Threshold Pharmaceuticals Reports Third Quarter 2015 Financial and Operational Results Marketwired
Oct-27-15 07:00AM  Threshold Pharmaceuticals Announces Preclinical Data Presentations on Tarloxotinib at the 2015 AACR-NCI-EORTC Meeting Marketwired
Oct-13-15 07:00AM  Threshold Pharmaceuticals Receives Two U.S. Patents for Tarloxotinib Bromide Marketwired
Sep-28-15 02:04PM  ETFs with exposure to Threshold Pharmaceuticals, Inc. : September 28, 2015 -7.78%
10:21AM  Threshold Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : September 28, 2015
Sep-15-15 11:17AM  According to Wall Street, These Small-Cap Biotech Stocks Could Triple at Motley Fool
Sep-08-15 07:00AM  Threshold Pharmaceuticals Appoints Mark Hopkins, J.D., Ph.D., Vice President of Intellectual Property and Assistant General Counsel Marketwired
Sep-03-15 07:00AM  Threshold Pharmaceuticals Announces Presentation and Webcast at the Rodman & Renshaw Annual Global Investment Conference Marketwired
Aug-27-15 07:00AM  Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin Marketwired
Aug-26-15 01:24PM  Threshold Pharmaceuticals, Inc. Earnings Q2, 2015
Aug-11-15 07:00AM  Threshold Pharmaceuticals and ATOMIC Initiate First Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in Patients With Advanced EGFR-Mutant, T790M-Negative Non-Small Cell Lung Cancer (NSCLC) Marketwired
Aug-10-15 09:24AM  2 Biotech Stocks That Could Skyrocket In The Next 12 Months
Aug-08-15 12:01PM  3 Top Biotech Stocks for High-Risk Investors at Motley Fool
Threshold Pharmaceuticals, Inc. discovers and develops therapeutic agents that target tumor cells for the treatment of cancer patients in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and advanced pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma; and Phase I/II clinical trials for multiple myeloma. The company is also involved in the study of evofosfamide in investigator sponsored trials, including Phase I/II clinical trials for glioblastoma; Phase I clinical trials for advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors; Phase II clinical trials for glioblastoma and pancreatic neuroendocrine tumors; Phase I clinical trials for advanced solid tumors; and Phase I/II clinical trials for advanced kidney cancer or liver cancer. In addition, it engages in developing Tarloxotinib, a hypoxia-activated EGFR tyrosine kinase inhibitor, which is in two Phase II clinical trials for patients with advanced non-squamous non-small cell lung cancer, as well as patients with squamous cell carcinomas of the head, neck, or skin; and [18F]-HX4, an investigational PET imaging agent for hypoxia. The company has a license agreement with Merck KGaA to co-develop and commercialize evofosfamide; license agreement with Auckland UniServices Ltd. for the development program based on Tarloxotinib; and license agreement with Eleison Pharmaceuticals, Inc. for the manufacture, development, and commercialization of glufosfamide for the treatment of cancer in humans and animals, as well as other uses. It also has a collaboration with the National Cancer Institute to study TH-3424, a drug candidate for the treatment of cancer. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.